Keywords: roche, mabthera, yields, strong, data, cll, early

Roche's MabThera yields strong data in CLL

Article | 17 December 2007

Print This

Early results from two Phase II trials tracking the outcome of patients with chronic lymphocytic leukemia treated with Roche's MabThera ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in